Cyanotech to Go Private via Reverse/Forward Stock Split, Forcing Out Small Shareholders
Summary
Cyanotech Corporation is executing a "going private" transaction through a 400-for-1 reverse stock split, followed by a 1-for-400 forward split, to reduce its shareholder count below 300 and deregister from the SEC, eliminating public reporting obligations.
Key Events
-
Going Private Transaction
Cyanotech will execute a 400-for-1 reverse stock split followed by a 1-for-400 forward split to reduce its shareholder count below 300, enabling it to cease being a public reporting company.
-
Deregistration from SEC
The company intends to terminate its SEC registration and suspend reporting obligations, citing significant cost savings, which were approximately $560,000 in 2025.
-
Forced Cash-Out for Small Shareholders
Stockholders owning fewer than 400 pre-split shares will be involuntarily cashed out at $0.47 per share, which is below the current market price of $0.499404.
-
Loss of Public Market Liquidity
The company's common stock will no longer be quoted on the OTCQB, with potential for reduced liquidity and transparency on lower OTC tiers.
Analysis
This SC 13E3 filing signals a critical shift for Cyanotech Corporation as it moves to terminate its public reporting status. The company aims to reduce administrative and compliance costs, which were approximately $560,000 in 2025, a substantial amount relative to its market capitalization. However, this transaction will significantly impact public shareholders. Those holding fewer than 400 shares will be involuntarily cashed out at $0.47 per share, which is below the current stock price of $0.499404. The deregistration will lead to a loss of transparency, reduced liquidity, and the cessation of quotation on the OTCQB, potentially moving to a lower, less regulated tier of the OTC Markets. While the company benefits from cost savings, the loss of public status and forced shareholder exit at a discount represents a material negative for investors.
At the time of this filing, CYAN was trading at $0.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.21 to $0.78. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.